Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial

被引：0
|
作者：
Cuzick, J. [1 ]
机构：
[1] Wolfson Inst Prevent Med, London, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [11] Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
    Sestak, Ivana
    Distler, Wolfgang
    Forbes, John F.
    Dowsett, Mitch
    Howell, Anthony
    Cuzick, Jack
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3411 - 3415
  • [12] A Quantified Risk-Scoring System for the Recurrence of Meningiomas: Results From a Retrospective Study of 392 Patients
    Zhu, Zhangzhang
    Wang, Chengde
    Xu, Jiadong
    Wang, Chunyong
    Xia, Lei
    Li, Qun
    Lu, Jianglong
    Cai, Lin
    Zheng, Weiming
    Su, Zhipeng
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [13] The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial
    Eastell, R.
    Coleman, R.
    Mansel, R.
    Bianco, A.
    Nagykalnai, T.
    Cuzick, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S109 - S109
  • [14] Risk factors for fracture: 5-year results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S27 - S27
  • [15] Breast Cancer Index and comparative analysis of late distant recurrence risk with results from the TEAM trial
    Bartlett, John M. S.
    Zhang, Yi
    Pond, Gregory
    Wong, Jenna
    Xu, Keying
    Spears, Melanie
    Mallon, Elizabeth
    Taylor, Karen
    Hasenburg, Annette
    Markopoulos, Christos
    Dirix, Luc
    Seynaeve, Caroline
    van de Velde, Cornelis J. H.
    Rea, Daniel
    Brufsky, Adam
    Stal, Olle
    Sgroi, Dennis
    Schnabel, Catherine
    Treuner, Kai
    Bayani, Jane
    CANCER RESEARCH, 2024, 84 (09)
  • [16] Impact of prior chemotherapy regimens on the relative efficacy of endocrine therapy: an exploratory analysis of data from the ATAC('Arimidex', Tamoxlfen, Alone or in Combination) trial on behalf of the ATAC Trialists' Group
    Nabholtz, Jean-Marc
    Buzdar, Aman
    ANNALS OF ONCOLOGY, 2004, 15 : 55 - 56
  • [17] Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
    I Sestak
    R Kealy
    M Nikoloff
    M Fontecha
    J F Forbes
    A Howell
    J Cuzick
    British Journal of Cancer, 2012, 107 : 230 - 233
  • [18] Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
    Sestak, I.
    Kealy, R.
    Nikoloff, M.
    Fontecha, M.
    Forbes, J. F.
    Howell, A.
    Cuzick, J.
    BRITISH JOURNAL OF CANCER, 2012, 107 (02) : 230 - 233
  • [19] Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial
    Eastell, R.
    Adams, J. E.
    Clack, G.
    Howell, A.
    Hannon, R. A.
    Cuzick, J.
    Mackey, J. R.
    Beckmann, M.
    Coleman, R.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S84 - S84
  • [20] Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial
    Sell, Ville
    Ettala, Otto
    Perez, Ileana Montoya
    Jarvinen, Riikka
    Pekkarinen, Tarmo
    Vaarala, Markku
    Seppanen, Marjo
    Liukkonen, Tapani
    Marttila, Timo
    Aaltomaa, Sirpa
    Kaasinen, Eero
    Bostrom, Peter J.
    WORLD JOURNAL OF UROLOGY, 2020, 38 (04) : 1001 - 1007
12345